2015
12/31/2015 #144: Licensing Deals in Year 2015: Early Stage Endocrine Assets Scored Big
12/24/2015 #143: Happy Holidays from Life Science Nation
12/17/2015 #142: RESI Innovation Challenge: Participating Startups Announced
12/10/2015 #141: How the Affordable Care Act Affects Investor Mandates
12/03/2015 #140: 4 Tips on How to Get the Most Out of Partnering
11/25/2015 #139: LSN Wishes You A Happy Thanksgiving And A Fruitful Fundraising Campaign
11/19/2015 #138: Pitching to a Foundation? Be Prepared for These Issues
11/12/2015 #137: Rising Opportunities in Precision Medicine
11/05/2015 #136: Early Stage Global Investors Converging on RESI@JPM
10/29/2015 #135: Medtech Family Offices Talk Trends and Evaluation Criteria
10/22/2015 #134: To Raise Capital, Go Outbound Without Assumptions
10/15/2015 #133: Life Science CVC Panelists Discuss Investment Trends
10/08/2015 #132: Common Pitfalls In Managing A Therapeutic Asset
10/01/2015 #131: September Mandate Roundup: Asian Based Investors Continue to Show Interest in Global Technologies
09/24/2015 #130: Seeking Capital? Learn A Little Sales (There I Said It)
09/17/2015 #129: RESI Innovation Challenge Winners Announced
09/10/2015 #128: It’s Not Too Late to Register – Check out the RESI Program Guide
09/03/2015 #127: How to Write a Compelling Partnering Message
08/27/2015 #126: What Does It Take to Get a Meeting: The Targeted Outreach Curve
08/20/2015 #125: Innovation In Spotlight at RESI
08/13/2015 #124: Breakdown of Investors You Can Meet at RESI Boston
08/06/2015 #123: Using CRM to Build A Data-Driven, Transparent Fundraising Campaign
07/30/2015 #122: Winning Your Next Stage Investment-One Competition at a Time
07/23/2015 #121: Therapeutic Financing Rounds in 2015: Gene Therapy Outpaces Antibodies in Early Stage Investment
07/16/2015 #120: RESI Innovation Challenge Now Accepting Applications
07/09/2015 #119: Keeping It Fresh: The Importance of Up-to-Date Investor Data
07/02/2015 #118: Back to Boston and Bigger than Ever: RESI Conference on September 16th
06/25/2015 #117: Family Offices and Walled Gardens
06/18/2015 #116: RESI Wraps Up in Houston and Heads Back to Boston
06/11/2015 #115: Winners Announced From Latest RESI Innovation Challenge
06/04/2015 #114: LSN Summer Chapter Series: Issue #2
05/28/2015 #113: An LSN Summer Chapter Series
05/21/2015 #112: Getting the Most from a 30-Minute Investor Meeting
05/14/2015 #111: How Do Investors Assess a Management Team?
05/07/2015 #110: New Models Emerge to Aid Scientist-Entrepreneurs Journey from Bench to Bedside
04/30/2015 #109: If You Build It, They Will Come!
04/23/2015 #108: Things to Consider in Building Big Pharma Partnerships
04/16/2015 #107: Are You a Fit for the Greater China Market?
04/09/2015 #106: JLABS Collaborates with LSN and TMCx for Early Stage Investor Event
04/02/2015 #105: Researching Life Science Investors: Webinar Now Available
03/26/2015 #104: 6 Takeaways from Women In Bio Shark Tank
03/19/2015 #103: Calling All Innovators! RESI Innovation Challenge: Applications Now Open
03/12/2015 #102: The Magnificent Seven-Fundraising Challenges Facing Life Science Entrepreneurs
03/05/2015 #101: Building Your Brand: The Importance of a Consistent Message
02/26/2015 #100: A Look Back at Our Top Five Articles
02/19/2015 #99: Texas Medical Center to Host Redefining Early Stage Investments Conference
02/12/2015 #98: LSN Fundraising Boot Camp at the 10th Non-Dilutive Funding Summit
02/05/2015 #97: Asia-Based Investors Are Increasingly Seeking Global Innovation
01/29/2015 #96: The Life Science Venture Philanthropy Landscape
01/22/2015 #95: RESI 4 San Francisco: Compelling Connections Created, Dialogues Begun, the Game’s Afoot
01/08/2015 #94: RESI 4 Is Approaching – Check Out the Program Guide
2014
12/18/2014 #93: Year-End Roundup: Investor Mandates
12/11/2014 #92: Do You Have the Right Investor List?
12/04/2014 #91: Partnering Based on Fit!
11/27/2014 #90: Life Science Nation and FreeMind Group Align In San Francisco for Early Stage Fundraising Executives
11/20/2014 #89: 11 Tips for Creating a Successful Pitch Deck
11/13/2014 #88: Looking For Capital? The Top Three Questions For Fundraising CEOs Before You Start
11/06/2014 #87: 109 Investors from 20 Countries- October Mandate Roundup
10/30/2014 #86: 10 Steps to a Life Science Fundraising Campaign
10/23/2014 #85: Family Offices Investing in Early Stage Medtech: RESI 4 Announces First Panel
10/16/2014 #84: Scientist-Entrepreneurs and Investors Made Compelling Connections at RESI 3
10/09/2014 #83: Successful Life Science Entrepreneurs Tell Their Tales from the Road
10/02/2014 #82: Major Corporate Venture Funds Discuss Early Stage Investing
09/26/2014 #81: Video: Five Family Offices Discuss Life Science Investment at RESI 3
09/19/2014 #80: RESI Innovation Challenge: Who Knocked it Out of the Park at the Home of the Boston Red Sox?
09/11/2014 #79: If You’re Serious About Raising Capital, Check Out The RESI Program
09/04/2014 #78: Family Offices Investing Direct
08/28/2014 #77: Live Investor Leads Sent to Your Mailbox
08/21/2014 #76: LSN Announces RESI Partnering Platform
08/14/2014 #75: Preclinical and Phase I Investors Leading the Charge at RESI
08/07/2014 #74: The Place to Meet Early Stage Investors
07/31/2014 #73: July Roundup: 76 Mandates
07/24/2014 #72: Virtual Pharma Partners: Guiding Assets to Commercialization
07/17/2014 #71: Mapping Out the Early Stage Fundraising Dilemma
07/10/2014 #70: LSN Garners 56 New Investor Mandates in June 2014
07/03/2014 #69: East Meets West
06/26/2014 #68: The Life Science Executive’s Fundraising Manifesto:Why I Wrote This Book
06/19/2014 #67: LSN Announces Life Science Fundraising Accelerator
06/12/2014 #66: LSN Releases Book: The Life Science Executive’s Fundraising Manifesto
06/05/2014 #65: Investors Want Therapeutics, Devices and Diagnostics – LSN’s 20 Most Recent Mandates
05/29/2014 #64: It’s Raining Investors Seeking Early Stage
05/22/2014 #63: The Road to Commercialization: Do Life Science Incubators Deliver on Their Promise?
05/15/2014 #62: Save the Date for the Next RESI Conference: September 17, 2014
05/08/2014 #61: Filtering the Noise: How Life Science Investors Manage Prospects
05/01/2014 #60: Do Traditional Marketing Techniques Apply to Life Sciences?
04/24/2014 #59: The Importance of Single-Asset Focus
04/17/2014 #58: Top 5 Indications For Non-VC Early Stage Investors
04/10/2014 #57: Early Stage Investors Go Global
04/03/2014 #56: Stars Align for Rare Disease Investment
03/27/2014 #55: Women CEOs Lead the Day at the RESI Innovation Challenge
03/20/2014 #54: Life Science Investors Step Into the Spotlight
02/21/2014 #53: Getting Non-fits Off the Plate
02/06/2014 #52: Formulating the Introductory Email to Potential Investors
01/30/2014 #51: A Deep Dive: LSN Family Office Investor Mandates
01/23/2014 #50: See It for Yourself! LSN Investor Database Demo
01/09/2014 #49: LSN Published in Nature Bioentrepreneur: “Beyond Venture Capital”
2013
12/19/2013 #48: The Market Strata for Early Stage Innovation
12/12/2013 #47: Adapting Your Start-up to the Investor Mindset
12/05/2013 #46: CRO Trends in 2014
11/21/2013 #45: LSN Announces RESI II
11/14/2013 #44: LSN Database Feature: Non-VC Interest in Early Stage Biotech
11/07/2013 #43: Next Generation Philanthropy, and How to make it Happen
11/01/2013 #42: Funding from the Crowd
10/25/2013 #41: Phone Canvassing Issue
10/17/2013 #40: Email Marketing Issue
10/10/2013 #39: Validating the New Investment Dynamic Between the US and EU
10/03/2013 #38: Creating a Dialogue with Life Science Investors
09/26/2013 #37: Hello World…ABC Life Science Company is Raising Capital!
09/20/2013 #36: RESI Conference Recap: A Great Day For Early Stage Life Sciences
09/12/2013 #35: The History of the RESI Conference
08/30/2013 #34: The Chasm of Skepticism
08/15/2013 #33: The Last Three Feet: Vetting and Grooming the Scientists for Success
08/09/2013 #32: Gorillas at the Table: Corporate Venture Capital
08/01/2013 #31: Crowdfunding: The Good, the Bad, & the Ugly
07/25/2013 #30: Lines Blurring between VC, PE and Hedge Funds in Life Science Investing
07/19/2013 #29: 100+ Early Stage Life Science Investors Converge on Boston
07/11/2013 #28: Electronic Patient Records’ Impact on Clinical Testing
06/27/2013 #27: Winds of Change in the CRO Space
06/20/2013 #26: NIH Resurrecting Big Pharma Castoffs
06/13/2013 #25: The Importance of Investor Fit
06/06/2013 #24: Redefining Early Stage Investments
05/23/2013 #23: Investment Banks – Family Office Direct Investment Trend
05/17/2013 #22: Crowdfunding and the Life Science Arena
05/09/2013 #21: Science and Investing in an Overhyped World
05/02/2013 #20: The Emperor’s New Clothes
04/25/2013 #19: Big Device Firms Focusing on Early Stage Opportunities
04/18/2013 #18: Elucidating the Timeline to Capital
04/11/2013 #17: Venture Philanthropy Providing Capital for Early Stage Science
04/04/2013 #16: Mapping Your Fundraising Strategy
03/28/2013 #15: The Mantra and Myths of Capital Efficiency
03/22/2013 #14: Life Science Players Adopt a Pervasive Global Approach
03/14/2013 #13: Personalized Medicine Trend Spurs Investments in Diagnostics
03/07/2013 #12: CRO Trends in 2013
02/27/2013 #11: How to Easily Select Investors that May Be a Fit
02/21/2013 #10: Outsourcing your Fundraising Efforts: The Conundrum for Life Science CEOs
02/12/2013 #9: Epigenetics, Antibodies & Orphan Therapeutics: Leading Biotech Licensing Trends in 2013
02/05/2013 #8: The Straightest Line to Commercialization
01/29/2013 #7: Leveraging Outbound Marketing for Fundraising Campaigns
01/22/2013 #6: Validating the Family Office Life Science Investment Strategy
01/15/2013 #5: Branding, Messaging & Identifying Investor Targets
01/08/2013 #4: What’s New in the “Valley of Death”?
2012
12/18/2012 #3: The Genealogy of Family Offices
12/11/2013 #2: Family Offices: The New VCs
12/05/2013 #1: Life Science Nation Newsletter
Next Phase Newsletter 
Leave a comment